Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSK3486 vs Propofol for Sedation in ICU Patients on Mechanical Ventilation
NCT04620031Phase 3Completed
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Dec 2020
- Primary completion
- Jun 2021
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of cipepofol in sedation (2 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoint: Success rate of sedation at 24 hours. Started Dec 2020; status: completed.
02
Drugs
cipepofol
03
Conditions
sedation
Beyond the preview
Go deeper on NCT04620031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04620031.